Defining neuroblastoma: From origin to precision medicine
Neuro-Oncology · 05.12.2024 · 26 (12) · 2174-2192
DOI: 10.1093/neuonc/noae152 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuro-Oncology, online erschienen am 05.08.2024. Verfasst von Lourdes Sainero-Alcolado und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet, Stockholm SE-17165, Sweden. Hauptthemen laut MEDLINE: Neuroblastoma, Precision Medicine. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Swedish Childhood Cancer Foundation.
Abstract (Originalsprache)
Neuroblastoma (NB), a heterogenous pediatric tumor of the sympathetic nervous system, is the most common and deadly extracranial solid malignancy diagnosed in infants. Numerous efforts have been invested in understanding its origin and in development of novel curative targeted therapies. Here, we summarize the recent advances in the identification of the cell of origin and the genetic alterations occurring during development that contribute to NB. We discuss current treatment regimens, present and future directions for the identification of novel therapeutic metabolic targets, differentiation agents, as well as personalized combinatory therapies as potential approaches for improving the survival and quality of life of children with NB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet, Stockholm SE-17165, Sweden.
- Department of Women's and Children's Health, Karolinska Institutet, Stockholm SE-17177, Sweden.
- Paediatric Oncology Unit, Astrid Lindgren's Children Hospital, Solna SE-17164, Sweden.
- Department of Laboratory Medicine, Division of Translational Cancer Research, Lund University, Lund SE-22381, Sweden.
ORCID-Profile: Judit Liaño-Pons, Marie Arsenian-Henriksson
Förderung
- Swedish Research Council
- Swedish Childhood Cancer Foundation
Zitieren
APA
Sainero-Alcolado, L., Sjöberg Bexelius, T., Santopolo, G., Yuan, Y., Liaño-Pons, J., & Arsenian-Henriksson, M. (2024). Defining neuroblastoma: From origin to precision medicine. Neuro-Oncology, 26(12), 2174-2192. https://doi.org/10.1093/neuonc/noae152
Vancouver
Sainero-Alcolado L, Sjöberg Bexelius T, Santopolo G, Yuan Y, Liaño-Pons J, Arsenian-Henriksson M. Defining neuroblastoma: From origin to precision medicine. Neuro-Oncology. 2024;26(12):2174-2192. doi:10.1093/neuonc/noae152
BibTeX
@article{SaineroAlcolado2024,
author = {Sainero-Alcolado, Lourdes and Sjöberg Bexelius, Tomas and Santopolo, Giuseppe and Yuan, Ye and Liaño-Pons, Judit and Arsenian-Henriksson, Marie},
title = {Defining neuroblastoma: From origin to precision medicine},
journal = {Neuro-Oncology},
year = {2024},
volume = {26},
number = {12},
pages = {2174--2192},
doi = {10.1093/neuonc/noae152}
}
EUVIMED